$BRNS News
Last published 2mo ago
- 2mo agoBRNSBarinthus Bio Provides Update on Proposed Combination with Clywedog TherapeuticsGlobeNewswireScheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreementScheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq
- 3mo agoBRNSBarinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate DevelopmentsGlobeNewswireProposed combination with Clywedog Therapeutics Inc. ("Clywedog") progressing towards closingCompleted enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac
- 6mo agoBRNSBarinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate DevelopmentsGlobeNewswireProposed combination with Clywedog Therapeutics Inc. ("Clywedog") progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important
- 8mo agoBRNSBarinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate DevelopmentsGlobeNewswireProposed combination with Clywedog Therapeutics Inc. ("Clywedog") to create a differentiated company focusing on clinical metabolic and autoimmune pipeline assets and to build on the Company's base of high caliber
- 11mo agoBRNSBarinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac DiseaseGlobeNewswireVTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000 was well-tolerated with no treatment-related SAEs The MAD
- 1y agoBRNSBarinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate DevelopmentsGlobeNewswireSingle ascending dose data readout for VTP-1000 expected before the end of 2025Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026Proposed combination with
- 1y agoBRNSChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus TherapeuticsPR NewswireChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and...
- 1y agoBRNSBarinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune DiseasesGlobeNewswireThe combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1 and Type 2 Diabetes
- 1y agoBRNSBarinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate DevelopmentsGlobeNewswireThe final cohort of the single ascending dose (SAD) part of the Phase 1 AVALON trial initiated, with the SAD data readout expected early in the fourth quarter of 2025;The multiple ascending dose (MAD) part of the AVALON
- 1y agoBRNSBarinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025ACCESS NewswireOXFORD, GB AND GERMANTOWN, MD / ACCESS Newswire / June 9, 2025 / Barinthus Biotherapeutics plc announced that Bill Enright, CEO, will be presenting at the Investor Summit Virtual taking place on June 10.About Barinthus
- 1y agoBRNSBarinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate DevelopmentsGlobeNewswireHighly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025;Initiation of VTP-1000 multiple ascending dose
- 1y agoBRNSBarinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate DevelopmentsGlobeNewswireStrategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000) in the clinic,
- 1y agoBRNSBarinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11ACCESS NewswireNEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.About Barinthus
- 1y agoBRNSBarinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial UpdateGlobeNewswirePrioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identifiedExtending the cash runway
- 1y agoBRNSBarinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific OfficerGlobeNewswireOXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio"), today announced the promotion of Geoffrey Lynn, M.D., Ph.D. to Chief
- 1y agoBRNSBarinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb SeroconversionGlobeNewswireEight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC therapy seroconverted to HBsAb positivity. OXFORD, United Kingdom, Nov. 15,
- 1y agoABUSBRNSArbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis BGlobeNewswireSignificantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously23% of participants receiving
- 2y agoBRNSBarinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial ResultsGlobeNewswireOXFORD, United Kingdom, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to
- 2y agoBRNSBarinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November ConferencesGlobeNewswireOXFORD, United Kingdom, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to
- 2y agoBRNSBarinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate CancerGlobeNewswireInvestigational immunotherapy, VTP-300, is being evaluated as part of a potential functional cure regimen for chronic Hepatitis B.Interim data update for HBV003 anticipated in Q4 2024.Data update for PCA001 anticipated
- 2y agoBRNSBarinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac DiseaseGlobeNewswireInvestigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease.An estimated one in 100 people globally suffer from celiac disease, for which no approved
- 2y agoBRNSBarinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial ResultsGlobeNewswireOXFORD, United Kingdom, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates, provided an
- 2y agoBRNSRCUSSGMTSNDX+2Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of DirectorsGlobeNewswireSAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to
- 2y agoBRNSBarinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus InfectionsGlobeNewswireThe development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized.The pipeline prioritization is expected to result in a reduction in workforce of approximately 25% and
- 2y agoABUSBRNSBarinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis BGlobeNewswireIn the HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for
- 2y agoBRNSBarinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024GlobeNewswireTwo abstracts highlighting the Company's lead hepatitis B-focused asset will be presented as poster and oral presentations.More mature interim data to be presented at EASL following abstract data cuts earlier in the
- 2y agoBRNSBarinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate DevelopmentsGlobeNewswireOXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide
- 2y agoBRNSBarinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical OfficerGlobeNewswireOXFORD, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic
- 2y agoBRNSBarinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) InfectionsGlobeNewswirePrimary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events (AEs) or serious AEs (SAEs). Positive trends in clearance rate for both high-risk (hr)HPV
- 2y agoBRNSBarinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate DevelopmentsGlobeNewswireOXFORD, United Kingdom, March 20, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, announced its financial results for the year ended December 31, 2023, and an overview of
- 2y agoBRNSBarinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate MilestonesGlobeNewswireCash runway anticipated to be extended from Q2 2025 to Q4 2025Data from multiple Phase 1 and 2 clinical trials expected in 2024 OXFORD, United Kingdom, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc
- 2y agoBRNSNew partnership aims to advance vaccine against MERS coronavirusGlobeNewswireCEPI to invest funding of up to $34.8 million to Barinthus Bio in addition to funds previously committed to the University of Oxford to develop and stockpile a ready reserve of emergency MERS vaccine candidate,
- 3y agoABUSBRNSBarinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLDGlobeNewswireInitial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline.In HBV003, 31% of participants with screening HBsAg level of ≤200 IU/mL had
- 3y agoBRNSBarinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewswireOXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, today announced its financial results for the third quarter of 2023 and provided an
- 3y agoABUSBRNSArbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®GlobeNewswireThe combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then VTP-300 show early signs
- 3y agoVACCBRNSVaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and CancerGlobeNewswireNew Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc